Skip to top bar
Skip to header
Skip to content
Skip to footer
CS
>
Publications
>
Publication Records - Search
Publication Records - Search
Advanced search
Repository
Selected publication/outcome records
Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? (2015)
Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění? (2015)
Vplyv terapie monoklonálnými protilátkami u chronickej lymfocytovej leukémie a B-lymfómov na expresiu antigénu CD20 (2015)
Využití celoexomového sekvenování (2016)
Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. (2016)
Vyřazení genu CD20 pomocí CRISPR/Cas9 knockoutu nezpůsobí žádný defekt v BCR signalizaci u B-lymfoidních malignit (2016)
Příprava linií rezistentních k působení anti-CD20 monoklonálních protilátek a analýza signálních drah u B-lymfoidních malignit (2016)
Nové technologie v medicíně: CAR T lymfocyty – převratná metoda v léčbě hematologických malignit (2016)
Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies (2016)
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated (2016)
B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia (2017)
CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies (2017)
Exomové sekvenování v diagnostice dědičných trombocytopenií (2017)
Význam a využití NGS v diagnostice dědičných trombocytopenií. (2017)
B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia (2017)
B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile. (2017)
Mechanisms of resistance to monoclonal antibodies in CLL (2017)
Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies (2017)
MEK inhibitors block growth of Ataxia Telangiectasia Mutated (ATM) mutant lung tumors (2017)
ASH 2017 – novinky laboratorní. (2018)
Dědičné trombocytopenie (2018)
Epigenetický screening buněk rezistentních k rituximabu odhalil možnou roli inhibitorů Aurora kináz v regulaci exprese CD20 (2018)
Epigenetic drug screen on resistant CLL cells reveals Aurora kinase inhibitors as enhancers of CD20 expression and sensitizers to treatment with CD20 monoclonal antibodies (2018)
Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression (2018)
Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets (2018)
Unexpected role of Aurora kinase inhibitors in CD20 expression (2018)
CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia (2018)
Functional genomics to reveal novel opportunities for CD20 antibody therapy of B-cell malignancies (2018)
Functional genomics to predict novel targets for personalized therapy of B-cell malignancies (2018)
Functional genomics to reveal novel opportunities for CD20 antibody therapy of B-cell malignancies (2018)
T lymfocyty s chimerickým receptorem (CAR): revoluce v imunoterapii nádorů (2018)
Performance of α-CD19 Chimeric Antigen Receptor T cells in genetically defined classes of Chronic Lymphocytic Leukemia (2019)
Epigenetic drug screen on CD20 immunotherapy resistant cells revealed possible role of Aurora kinase inhibitors in CD20 expression regulation. (2019)
Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells (2020)
Revoluce v imunoterapii nádorů: CAR-T lymfocyty (2019)
Epigenetic drug screen of a CD20-low expressing cell line revealed an unexpected role of Aurora kinase inhibitors in CD20 expression. (2019)
The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia (2019)
CRISPR/Cas9 gene editing and functional screening in chronic lymphocytic leukemia (2019)
Epigenetic drug screen of CD20-low expressing cell line revealed possible treatment target. (2019)
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells (2020)
Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia (2020)
Combination of epigenetic drug screen and CRISPR knockout screen revealed involvement of aurora kinases and Cullin 3 in CD20 regulation (2020)
Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20 (2020)
The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. (2020)
Impact of genetics on the performance of anti-CD 19 chimeric antigen receptor T cells in chronic lymphocytic leukemia (2020)
CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia (2020)
Combination of epigenetic drug screen and CRISPR knockout screen as an unbiased approach to reveal possible CD20 therapy improvement (2020)
Functional analysis of germlineETV6 W380Rmutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia (2021)
Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs. (2021)
In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. (2021)
CD19 hypermethylation as an escape to CART-19. (2021)
Identification of biomarkers and escape mechanisms for CAR-T cell therapy in chronic lymphocytic leukemia. (2021)
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro (2021)
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia (2021)
Kongenitální neutropenie u dětí a dospělých (2021)
CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. (2021)
CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cells. (2021)
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells (2022)
Open Week (2021)
A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome (2022)
Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. (2022)
Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing (2022)
Prediction of novel treatment options for CLL and AML cells based on drug repurposing. (2022)
Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. (2022)
CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. (2022)
. Drug repurposing for venetoclax-resistant acute myeloid leukemia. (2022)
Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML (2022)
CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. (2022)
Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. (2022)
Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. (2022)
The use of functional genomics for advancing monoclonal antibody therapy of chronic lymphocytic leukemia (2022)
Funkční efekt nově identifikované varianty v genu CYCS u rodiny s trombocytopenií typu 4. (2023)
Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. (2023)
Nově identifikovaná varianta v genu CYCS u rodiny s trombocytopenií typu 4 a její funkční dopad. (2023)
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. (2023)
Efficacy of CD19-directed CAR-T cells against CLL and the possibilities for its further improvements. (2023)
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. (2023)
Chasing the epigenetic landscape to enhance CAR-T cell activity py preventing CD19 antigen escape in relapsed models. (2023)
Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. (2023)
CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. (2023)
Varianta v genu CYCS způsobující trombocytopenii 4 zvyšuje kaspázovou aktivitu. (2023)
CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. (2023)
Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells. (2023)
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies (2024)
A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study (2024)
Thieno[3,2-b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode (2024)
EXPLORING VENETOCLAX RESISTANCE MECHANISMS IN AML CELLS THROUGH GENOME-WIDE CRISPR SCREENS AND DRUG PROFILING (2024)
ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING (2024)
Remove all the items
Operations on the selected outcomes
Export and print
List of selected records
Other applications
Publications
Information System
Skip to top barSkip to headerSkip to contentSkip to footer
